Potential therapeutic applications of RNA cap analogs
| Autor: | Malwina Strenkowska, Jacek Jemielity, Joanna Kowalska, Marcin Ziemniak |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
RNA Caps
Drug RNA Cap Analogs medicine.medical_treatment media_common.quotation_subject Computational biology Biology Muscular Atrophy Spinal Neoplasms Endoribonucleases Drug Discovery medicine Humans RNA Messenger media_common Pharmacology Oligonucleotide EIF4E RNA Genetic Therapy Immunotherapy Oligonucleotides Antisense Biochemistry Protein Biosynthesis Eukaryotic Initiation Factor-4A RNA splicing Molecular Medicine RNA stabilization |
| Zdroj: | Future Medicinal Chemistry. 5:1141-1172 |
| ISSN: | 1756-8927 1756-8919 |
| DOI: | 10.4155/fmc.13.96 |
| Popis: | Cap analogs are chemically modified derivatives of the unique cap structure present at the 5´ end of all eukaryotic mRNAs and several non-coding RNAs. Until recently, cap analogs have served primarily as tools in the study of RNA metabolism. Continuing advances in our understanding of cap biological functions (including RNA stabilization, pre-mRNA splicing, initiation of mRNA translation, as well as cellular transport of mRNAs and snRNAs) and the consequences of the disruption of these processes – resulting in serious medical disorders – have opened new possibilities for pharmaceutical applications of these compounds. In this review, the medicinal potential of cap analogs in areas, such as cancer treatment (including eIF4E targeting and mRNA-based immunotherapy), spinal muscular atrophy treatment, antiviral therapy and the improvement of the localization of nucleus-targeting drugs, are highlighted. Advances achieved to date, challenges, plausible solutions and prospects for the future development of cap analog-based drug design are described. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|